3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pain
4
Colorectal Neoplasms
3
Adenoma
3
Urologic Neoplasms
2
Insulin Resistance
2
Urologic Diseases
1
Urolithiasis
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Thyroid Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Skin Neoplasms
1
Polycystic Ovary Syndrome
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Mobility Limitation
1
MRSA Colonization
1
Ilues
1
Hypothyroidism
1
Hydronephrosis
1
Head and Neck Neoplasms
1
Fatigue
1
Fasting
1
Disease
1
Depression
1
Colonoscopy
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Interventions
Gemcitabine
2
chondroitin sulfate, sodium hyaluronate drug combination
1
Water
1
Therapeutics
1
Radiotherapy
1
Multiparametric Magnetic Resonance Imaging
1
Mitomycin
1
Hyaluronic Acid
1
Epirubicin
1
Docetaxel
1
Chondroitin Sulfates
1
Anesthesia, Spinal
1
Anesthesia, General
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Non-Muscle Invasive Bladder Neoplasms
×
Water
×
Clear all
NCT01803295
2017-06-16
OPTIMA
UroGen Pharma Ltd.
Phase NA
Completed
80 enrolled